AlloVir, a Phase 2 biotech developing allogeneic T cell therapies for viral diseases, raised $276 million by offering 16.3 million shares at $17, the midpoint of the range of $16 to $18. The company offered 1.5 million more shares than anticipated. At pricing, the company commands a fully diluted market value of $1.1 billion.
AlloVir plans to list on the Nasdaq under the symbol ALVR. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as lead managers on the deal.
